Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Durvalumab's Real-World impact on endometrial cancer

NCT ID NCT06890273

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting real-world data from 150 women in Germany with advanced or recurrent endometrial cancer. Participants receive standard first-line treatment with chemotherapy plus durvalumab, followed by maintenance therapy with durvalumab alone or with olaparib. The goal is to see how well these treatments work in everyday practice and how they affect patients' quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy drug) combined with chemotherapy (carboplatin and paclitaxel), followed by maintenance with durvalumab alone or with olaparib
What this could lead to
If successful, this could provide real-world evidence that durvalumab-based therapy helps control advanced or recurrent endometrial cancer and improves patient quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also limited to a German population, which may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

150 patients with documented primary advanced (FIGO stage III or IV) or recurrent EC of epithelial histology (excluding sarcomas) who are eligible for first-line therapy with CPD followed by durvalumab or durvalumab and olaparib in line with the applicable SmPC within routine clinical practice will be recruited in Germany. The study allows recruitment of patients that already started and may have received up to 2 cycles of CPD. Inclusion of patients having started CPD will be capped to 25% for each cohort of the study population. Testing results for MMR status of the patients' tumor must be available. Patients must be willing and able to report PROs. Eligible patients will be included into the study after and independently of the treating physician's treatment and diagnostic decisions.

Ages

18 to 130 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged ≥ 18 years at the time of screening. * Patient has pathologically documented: * Primary advanced (FIGO III and IV) epithelial EC OR * Recurrent disease that is unlikely to be cured and where the multidisciplinary tumor board decision is systemic therapy. Carcinosarcomas are allowed, * Patient is intended or initiated to receive 1L CPD followed by maintenance therapy with durvalumab (dMMR cohort) or with durvalumab and olaparib (pMMR cohort) according to the SmPC of IMFINZI® and Lynparza®\* prior to enrollment. Recruitment of patients that already started and may have received up to 2 cycles of CPD is allowed but will be capped to 25% for each cohort of the study population. * Patient is eligible for treatment with durvalumab and/or olaparib as specified in the IMFINZI® and Lynparza® SmPC. The prescription of the medicinal product is clearly separated from the decision to include the patient in the study. * MMR-testing results of the patient's tumor are known. * Patient is willing and able to complete PRO questionnaires. * Patient can read and understand German, English, Arab, Russian or Turkish. * Signed written informed consent. Exclusion Criteria: * Patient has already received \>2 cycles of 1L CPD * Known hypersensitivity to carboplatin, paclitaxel, durvalumab and/or olaparib or any of the excipients of the drug. * Pregnancy or breast-feeding. * Unable to swallow orally administered medication. * Current or planned participation in an interventional clinical trial. * Current or planned systemic treatment of any tumor other than primary advanced or recurrent EC. * Patient has pathologically documented sarcoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    49 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Amberg, Germany

  • Research Site

    RECRUITING

    Bad Nauheim, Germany

  • Research Site

    RECRUITING

    Bautzen, Germany

  • Research Site

    RECRUITING

    Berlin, Germany

  • Research Site

    RECRUITING

    Bielefeld, Germany

  • Research Site

    RECRUITING

    Bonn, Germany

  • Research Site

    RECRUITING

    Borna, Germany

  • Research Site

    RECRUITING

    Bottrop, Germany

  • Research Site

    RECRUITING

    Brandenburg an der Havel, Germany

  • Research Site

    RECRUITING

    Braunschweig, Germany

  • Research Site

    RECRUITING

    Cologne, Germany

  • Research Site

    RECRUITING

    Dessau, Germany

  • Research Site

    RECRUITING

    Dresden, Germany

  • Research Site

    RECRUITING

    Ebersberg, Germany

  • Research Site

    RECRUITING

    Eggenfelden, Germany

  • Research Site

    RECRUITING

    Essen, Germany

  • Research Site

    RECRUITING

    Goslar, Germany

  • Research Site

    RECRUITING

    Greifswald, Germany

  • Research Site

    RECRUITING

    Gütersloh, Germany

  • Research Site

    RECRUITING

    Hamburg, Germany

  • Research Site

    RECRUITING

    Heilbronn, Germany

  • Research Site

    RECRUITING

    Homburg, Germany

  • Research Site

    RECRUITING

    Hösbach, Germany

  • Research Site

    RECRUITING

    Kiel, Germany

  • Research Site

    RECRUITING

    Krefeld, Germany

  • Research Site

    RECRUITING

    Kulmbach, Germany

  • Research Site

    RECRUITING

    Landshut, Germany

  • Research Site

    RECRUITING

    Leipzig, Germany

  • Research Site

    RECRUITING

    Limburg, Germany

  • Research Site

    RECRUITING

    Lüneburg, Germany

  • Research Site

    RECRUITING

    Magdeburg, Germany

  • Research Site

    RECRUITING

    Mainz, Germany

  • Research Site

    RECRUITING

    München, Germany

  • Research Site

    RECRUITING

    Neuruppin, Germany

  • Research Site

    RECRUITING

    Neuss, Germany

  • Research Site

    RECRUITING

    Nuremberg, Germany

  • Research Site

    RECRUITING

    Plauen, Germany

  • Research Site

    RECRUITING

    Rotenburg (Wümme), Germany

  • Research Site

    RECRUITING

    Siegen, Germany

  • Research Site

    RECRUITING

    Solingen, Germany

  • Research Site

    RECRUITING

    Stendal, Germany

  • Research Site

    RECRUITING

    Torgau, Germany

  • Research Site

    RECRUITING

    Traunstein, Germany

  • Research Site

    RECRUITING

    Unna, Germany

  • Research Site

    RECRUITING

    Wernigerode, Germany

  • Research Site

    RECRUITING

    Winnenden, Germany

  • Research Site

    RECRUITING

    Witten, Germany

  • Research Site

    RECRUITING

    Worms, Germany

  • Research Site

    RECRUITING

    Zittau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.